Next generation antibody drugs: pursuit of the 'high-hanging fruit'
暂无分享,去创建一个
[1] K. Jensen,et al. In vitro and ex vivo strategies for intracellular delivery , 2016, Nature.
[2] Qing Chai,et al. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. , 2015, Protein engineering, design & selection : PEDS.
[3] P. Moore,et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.
[4] Garrett M. Morris,et al. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.
[5] Damon L. Meyer,et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.
[6] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[7] R. Carano,et al. Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia , 2013, PloS one.
[8] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[9] S. Shin,et al. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration , 2017, Nature Communications.
[10] Ying Tang,et al. LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.
[11] A. Strosberg,et al. Monoclonal antibodies to purified muscarinic receptor display agonist-like activity. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Cragg,et al. Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization , 2014, The Journal of Immunology.
[13] P. Diot,et al. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors , 2011, Pharmaceutical Research.
[14] A. Lukashin,et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. , 2006, Cancer research.
[15] A. Tolcher. Antibody drug conjugates: lessons from 20 years of clinical experience. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] A. Abbott,et al. Failed Alzheimer’s trial does not kill leading theory of disease , 2016, Nature.
[17] C. Uyttenhove,et al. PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species. , 2017, International journal of pharmaceutics.
[18] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[19] Andreas Plückthun,et al. A quantitative comparison of cytosolic delivery via different protein uptake systems , 2017, Scientific Reports.
[20] M. Boyle,et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. , 1997, Blood.
[21] C. Witmer,et al. Factor VIII inhibitors in hemophilia A: rationale and latest evidence , 2013, Therapeutic advances in hematology.
[22] Janice M. Reichert,et al. Antibodies to watch in 2017 , 2016, mAbs.
[23] C. Riccardi,et al. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives , 2012, British journal of pharmacology.
[24] Rachel M. Devay,et al. Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9* , 2012, The Journal of Biological Chemistry.
[25] J. Zapata,et al. T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes , 2013, The Journal of Immunology.
[26] A. Coxon,et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types , 2010, Cancer biology & therapy.
[27] R. Foà,et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics , 2013, mAbs.
[28] P. Burke,et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index , 2015, Nature Biotechnology.
[29] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[30] N. Bodyak,et al. A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy. , 2015, Cancer research.
[31] A. Baruch,et al. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases , 2017, Hormone molecular biology and clinical investigation.
[32] T. Arora,et al. Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex , 2012, Science Translational Medicine.
[33] Jeffrey R. Chabot,et al. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. , 2016, Cell metabolism.
[34] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[35] M. Cragg,et al. Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.
[36] M. Satoh,et al. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. , 2015, Journal of pharmaceutical sciences.
[37] Qing-hui Zhou,et al. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. , 2010, Molecular pharmaceutics.
[38] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[39] A. Ford,et al. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.
[40] Ryan L. Kelly,et al. Chaperone proteins as single component reagents to assess antibody nonspecificity , 2017, mAbs.
[41] J. Wolchok,et al. Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .
[42] L. Weiner,et al. Mechanisms of action of therapeutic antibodies for cancer. , 2015, Molecular immunology.
[43] J. Ravetch,et al. Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.
[44] P. Freskgård,et al. Antibody therapies in CNS diseases , 2017, Neuropharmacology.
[45] J. Foote,et al. Immunogenicity of engineered antibodies. , 2005, Methods.
[46] W. Luk,et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.
[47] A. Yang,et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. , 2011, Cancer cell.
[48] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[49] M. Chiu,et al. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody , 2016, mAbs.
[50] K Dane Wittrup,et al. Target-independent variable region mediated effects on antibody clearance can be FcRn independent , 2016, mAbs.
[51] Albert Torri,et al. Antidrug Antibodies in Patients Treated with Alirocumab. , 2017, The New England journal of medicine.
[52] Z. Johnson,et al. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[53] J. Folkman,et al. Angiogenic factors. , 1987, Science.
[54] P. Ridker,et al. Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab , 2017, The New England journal of medicine.
[55] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[56] D. Chang,et al. Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies* , 1996, The Journal of Biological Chemistry.
[57] M. Sliwkowski,et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.
[58] Melissa L Geddie,et al. A novel screening method to assess developability of antibody-like molecules , 2015, mAbs.
[59] A. Mitra,et al. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches , 2017, Expert opinion on drug delivery.
[60] Alexander Staab,et al. A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.
[61] C. Dumontet,et al. Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.
[62] M. P. Griffin,et al. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.
[63] J. Ravetch,et al. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo , 2013, Proceedings of the National Academy of Sciences.
[64] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Bylesjo,et al. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab , 2015, Journal of Immunotherapy for Cancer.
[66] Xiaotong Wang,et al. Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations , 2013, Genome biology and evolution.
[67] A. D. de Fougerolles,et al. Nanobodies®† as inhaled biotherapeutics for lung diseases , 2017, Pharmacology & therapeutics.
[68] A. Holdorf,et al. AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[69] H. Kettenberger,et al. Developability assessment during the selection of novel therapeutic antibodies. , 2015, Journal of pharmaceutical sciences.
[70] T. Igawa,et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.
[71] P. Parren,et al. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells , 2017, The Journal of Immunology.
[72] E. M. Cook,et al. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions , 2016, The Journal of Immunology.
[73] K. Amighi,et al. Inhaled proteins: challenges and perspectives. , 2013, International journal of pharmaceutics.
[74] P. Baeuerle,et al. Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.
[75] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[76] W. Pardridge,et al. CSF, blood-brain barrier, and brain drug delivery , 2016, Expert opinion on drug delivery.
[77] N. Bartlett,et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[78] Carol F. Kirchhoff,et al. Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence , 2016, BioDrugs.
[79] J Feldschuh,et al. Prediction of the Normal Blood Volume: Relation of Blood Volume to Body Habitus , 1977, Circulation.
[80] A. West,et al. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. , 2013, Cell reports.
[81] M. Schrappe,et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients , 2013, Leukemia.
[82] D. Irvine,et al. Delivering safer immunotherapies for cancer , 2017, Advanced drug delivery reviews.
[83] Gary D Bader,et al. A draft map of the human proteome , 2014, Nature.
[84] K. Gadkar,et al. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics. , 2015, Investigative ophthalmology & visual science.
[85] J. Wolchok,et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] Y. Vugmeyster,et al. Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species , 2011, Pharmaceutical Research.
[87] Carlos Pineda,et al. Assessing the Immunogenicity of Biopharmaceuticals , 2016, BioDrugs.
[88] L. Aiello,et al. RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.
[89] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[90] U. Nielsen,et al. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic , 2015, Molecular Cancer Therapeutics.
[91] Jean-Christophe Leroux,et al. Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts. , 2016, Advanced drug delivery reviews.
[92] Jeffrey S Wagener,et al. Dornase alfa (Pulmozyme) , 2012, Current opinion in pulmonary medicine.
[93] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[94] K. Scearce-Levie,et al. Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.
[95] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[96] S. Lacy,et al. The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity , 2008, The Journal of Immunology.
[97] Z. Sauna,et al. Immunogenicity assessment during the development of protein therapeutics , 2018, The Journal of pharmacy and pharmacology.
[98] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[99] S. Quezada,et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.
[100] M. Chiu,et al. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody* , 2016, The Journal of Biological Chemistry.
[101] Ulrich Brinkmann,et al. The making of bispecific antibodies , 2017, mAbs.
[102] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[103] L. Zitvogel,et al. Rationale for anti-OX40 cancer immunotherapy. , 2016, European journal of cancer.
[104] R. Million,et al. Monoclonal antibody biosimilars , 2015, Nature Reviews Drug Discovery.
[105] G. Sármay,et al. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19 , 2014, mAbs.
[106] Ying Tang,et al. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies , 2015, mAbs.
[107] D. Neri,et al. Immunocytokines for cancer treatment: past, present and future. , 2016, Current opinion in immunology.
[108] W. Pardridge,et al. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies , 2016, Expert opinion on biological therapy.
[109] W. Xu,et al. Developability studies before initiation of process development , 2013, mAbs.
[110] Scott R. Presnell,et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. , 2009, Protein engineering, design & selection : PEDS.
[111] T. Dryja,et al. Long-acting protein drugs for the treatment of ocular diseases , 2017, Nature Communications.
[112] F. Malavasi,et al. Antibody mimicry, receptors and clinical applications. , 2017, Human antibodies.
[113] Y. Vugmeyster,et al. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.
[114] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[115] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[116] Matthew J. Brauer,et al. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex , 2015, EBioMedicine.
[117] Mark R Prausnitz,et al. Ocular delivery of macromolecules. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[118] R. Chanock,et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats , 1987, Journal of virology.
[119] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[120] T. Igawa,et al. Reduced elimination of IgG antibodies by engineering the variable region. , 2010, Protein engineering, design & selection : PEDS.
[121] P. Carter,et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.
[122] R. Minter,et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency , 2012, Cell Death and Differentiation.
[123] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[124] J. Ravetch,et al. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.
[125] T. Wilkinson,et al. Discovery of Functional Antibodies Targeting Ion Channels , 2015, Journal of biomolecular screening.
[126] E. Remaut,et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis , 2010, Mucosal Immunology.
[127] E. Lemarié,et al. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations , 2014, mAbs.
[128] R. Vonderheide,et al. Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer , 2013, Cancer Immunology Research.
[129] Tsukasa Suzuki,et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.
[130] Chunning Yang,et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence , 2017, Scientific Reports.
[131] C. Yang,et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.
[132] K. Tsumoto,et al. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design , 2015, Immunological reviews.
[133] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[134] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[135] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[136] Sandeep Kumar,et al. Potential aggregation prone regions in biotherapeutics , 2009, mAbs.
[137] P. Diot,et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[138] Herren Wu,et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.
[139] J. Oldenburg,et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.
[140] B. Pentelute,et al. Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen , 2014, Chembiochem : a European journal of chemical biology.
[141] M. Rebelatto,et al. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. , 2016, Cancer cell.
[142] J. Ravetch,et al. Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.
[143] C. Ware,et al. Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2 , 2005, Clinical Cancer Research.
[144] R. Majeti,et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.
[145] L. Khawli,et al. Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics* , 2015, The Journal of Biological Chemistry.
[146] Osami Kanagawa,et al. Hybrid antibodies can target sites for attack by T cells , 1985, Nature.
[147] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[148] Diego Ellerman,et al. Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.
[149] J. Dye,et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses , 2016, Science.
[150] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[151] Gary Walsh,et al. Biopharmaceutical benchmarks , 2000, Nature Biotechnology.
[152] H. Lyerly,et al. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1 , 2015, Cancer Immunology, Immunotherapy.
[153] C. J. Hutchings,et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors , 2017, Nature Reviews Drug Discovery.
[154] M. Tabrizi,et al. Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.
[155] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[156] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[157] K. Shitara,et al. Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.
[158] P. Parren,et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.
[159] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[160] R. Kelley,et al. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates , 2017, mAbs.
[161] Anuj Chaudhri,et al. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. , 2015, Molecular pharmaceutics.
[162] Michel Sadelain,et al. Therapeutic T cell engineering , 2017, Nature.
[163] Louis P Garrison,et al. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[164] H. Kohrt,et al. 4-1BB agonism: adding the accelerator to cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.
[165] Qing-hui Zhou,et al. Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse , 2010, Drug Metabolism and Disposition.
[166] A. Ashkenazi,et al. Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies , 2013, The Journal of experimental medicine.
[167] J. Marvin,et al. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.
[168] F. Bootz,et al. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. , 2016, Drug discovery today.
[169] H. Miyazaki,et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor , 2008, Nature Biotechnology.
[170] Olga Obrezanova,et al. Aggregation risk prediction for antibodies and its application to biotherapeutic development , 2015, mAbs.
[171] I. Weissman,et al. CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.
[172] A. Wimo,et al. The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.
[173] W. Pardridge,et al. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.
[174] P. Humphries,et al. The blood-retina barrier: tight junctions and barrier modulation. , 2012, Advances in experimental medicine and biology.
[175] D D Allen,et al. The blood-brain barrier and brain drug delivery. , 2006, Journal of nanoscience and nanotechnology.
[176] Matthew R. Levengood,et al. Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.
[177] Rony Dahan,et al. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. , 2016, Cancer cell.
[178] A. D. Nielsen,et al. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[179] Jennifer B. Webster,et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. , 2006, Protein engineering, design & selection : PEDS.
[180] Yu Cao,et al. An immunosuppressive antibody-drug conjugate. , 2015, Journal of the American Chemical Society.
[181] A. Plückthun,et al. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[182] G. V. Vande Woude,et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.
[183] A. Cheng-Lai,et al. Inhaled Insulin: A Clinical and Historical Review , 2017, Cardiology in review.
[184] T. Arvedson,et al. Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing , 2017 .
[185] Alexandra Lavoisier,et al. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection , 2014, mAbs.
[186] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[187] J. Zenilman,et al. Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A , 2014, Antimicrobial Agents and Chemotherapy.
[188] Eugene A Zhukovsky,et al. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. , 2016, Current opinion in immunology.
[189] A. Datta-Mannan,et al. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics , 2015, mAbs.
[190] L. Schwartz,et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. , 2001, The Journal of allergy and clinical immunology.
[191] Sung-Bae Kim,et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[192] E. Bremer. Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy , 2013, ISRN oncology.
[193] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[194] Jos H. Beijnen,et al. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[195] P. S. Andersen,et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.
[196] P. Lakatos,et al. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? , 2010, Current drug targets.
[197] D. Salinger,et al. Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies , 2011, Clinical pharmacokinetics.
[198] A. Ashkenazi. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. , 2015, The Journal of clinical investigation.
[199] Tom Vink,et al. Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 , 2016, Molecular Cancer Therapeutics.
[200] T. Igawa,et al. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131 , 2013, Protein engineering, design & selection : PEDS.
[201] K Dane Wittrup,et al. Biophysical properties of the clinical-stage antibody landscape , 2017, Proceedings of the National Academy of Sciences.
[202] T. Igawa,et al. pH-dependent antigen-binding antibodies as a novel therapeutic modality. , 2014, Biochimica et biophysica acta.
[203] T. Igawa,et al. Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity , 2014, mAbs.
[204] A. D. de Vos,et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.
[205] J. Nezu,et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases , 2017, Scientific Reports.
[206] G. Thurston,et al. Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs , 2017, Molecular Cancer Therapeutics.
[207] P. Hass,et al. An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. , 1998, Blood.
[208] K. Gregersen,et al. Single-Batch Production of Recombinant Human Polyclonal Antibodies , 2010, Molecular biotechnology.
[209] T. Hanke,et al. Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists , 2003, The Journal of experimental medicine.
[210] Lisa J. Bernstein,et al. A strategy for risk mitigation of antibodies with fast clearance , 2012, mAbs.
[211] N. Warne,et al. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[212] Jesse A. Stevenson,et al. Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics , 2014, mAbs.
[213] M. Breyer,et al. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys , 2016, mAbs.
[214] Rodrigo Dienstmann,et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. , 2015, Cancer discovery.
[215] D. Corti,et al. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease , 2016, Current Opinion in Immunology.
[216] M. Little,et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells , 2014, mAbs.
[217] A. Bardelli,et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations , 2016, Science Translational Medicine.
[218] C. Laurell,et al. Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. , 1974, Clinical chemistry.
[219] Wolfgang Schaefer,et al. The use of CrossMAb technology for the generation of bi- and multispecific antibodies , 2016, mAbs.
[220] F. Theil,et al. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins , 2016, Journal of immunology research.
[221] J. Byrd,et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. , 2014, Blood.
[222] R. Bateman,et al. Stop Alzheimer’s before it starts , 2017, Nature.
[223] Napoleone Ferrara,et al. Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.
[224] C. Volz,et al. Antibody therapies and their challenges in the treatment of age-related macular degeneration. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[225] Matthew J. Newman,et al. A review of blinatumomab, a novel immunotherapy , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[226] B. Burnett,et al. Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans , 2015, Nutrition Journal.
[227] M. Mcnamara,et al. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..
[228] Herren Wu,et al. Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.
[229] M. Shirts,et al. Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange , 2011, Pharmaceutical Research.
[230] Leonard A. Smith,et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[231] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[232] W WarneNicholas,et al. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011 .
[233] K. Garber. Industry 'road tests' new wave of immune checkpoints , 2017, Nature Biotechnology.
[234] T. Hanke,et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases , 2005, Annals of the rheumatic diseases.
[235] Gary Walsh,et al. Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.
[236] K Dane Wittrup,et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. , 2013, Protein engineering, design & selection : PEDS.
[237] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[238] H. Fu,et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.
[239] Yang Wang,et al. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches , 2014, mAbs.
[240] Kang-Yell Choi,et al. Screening-based approaches to identify small molecules that inhibit protein–protein interactions , 2017, Expert opinion on drug discovery.
[241] Piet Gros,et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.
[242] W. Pardridge,et al. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.
[243] Richard O'Kennedy,et al. Coming-of-Age of Antibodies in Cancer Therapeutics. , 2016, Trends in pharmacological sciences.
[244] Melanie A. Huntley,et al. Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies , 2016, Neuron.
[245] H. Wajant,et al. Principles of antibody-mediated TNF receptor activation , 2015, Cell Death and Differentiation.
[246] J. Desjarlais,et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. , 2012, The Journal of allergy and clinical immunology.
[247] Jihong Wang,et al. Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.
[248] G. A. Lazar,et al. Modulation of antibody effector function. , 2011, Experimental cell research.
[249] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[250] Paul H. Bessette,et al. Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index , 2013, Science Translational Medicine.
[251] S. Vermeire,et al. AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. , 2016, Journal of Crohn's & colitis.
[252] Herren Wu,et al. Insights into the molecular basis of a bispecific antibody's target selectivity , 2015, mAbs.
[253] G. A. Lazar,et al. Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.
[254] M. Glennie,et al. Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.
[255] D. Scheinberg,et al. Opportunities and challenges for TCR mimic antibodies in cancer therapy , 2016, Expert opinion on biological therapy.
[256] M. Robinson,et al. Oligoclonal antibodies to target the ErbB family , 2015, Expert opinion on biological therapy.
[257] K. Gunasekaran,et al. Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies* , 2013, The Journal of Biological Chemistry.
[258] R. Ober,et al. Targeting FcRn for the modulation of antibody dynamics. , 2015, Molecular immunology.
[259] D. Driver,et al. FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys , 2012, Drug Metabolism and Disposition.
[260] Tetsu Kobayashi,et al. Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.
[261] P. Parren,et al. Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy? , 2016, Current opinion in immunology.
[262] Y. Yonezawa,et al. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2 , 2015, Scientific Reports.
[263] M. Tsuchiya,et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. , 2005, Blood.
[264] M. Klempner,et al. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life , 2015, mAbs.
[265] C. Palomo,et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.
[266] J. Dumont,et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.
[267] H. Yamamoto,et al. Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies. , 1999, Hybridoma.
[268] S. Iyer,et al. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[269] Thomas Emrich,et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.
[270] G. Proetzel,et al. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. , 2014, Methods.
[271] P. Cooper,et al. FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric‐coated capsules in cynomolgus macaques , 2016, Pharmacology research & perspectives.
[272] Patrick Mayeux,et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.
[273] J. Desjarlais,et al. Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor , 2013, Arthritis & rheumatology.
[274] B. Carr,et al. Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.
[275] J. Foidart,et al. Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma. , 2012, American journal of respiratory cell and molecular biology.
[276] R. Tarran,et al. Inhaled protein/peptide-based therapies for respiratory disease , 2016, Molecular and Cellular Pediatrics.
[277] A. Urtti,et al. Pharmacokinetic aspects of retinal drug delivery , 2017, Progress in Retinal and Eye Research.
[278] Sunghoon Kim,et al. A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells , 2014, mAbs.
[279] S. Kadono,et al. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant , 2013, mAbs.
[280] K. Scearce-Levie,et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates , 2014, Science Translational Medicine.
[281] P. Hass,et al. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. , 2016, Molecular pharmaceutics.
[282] C. Uyttenhove,et al. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[283] B. Jakobsen,et al. Molecular Immunology , 2015 .
[284] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[285] N. Tsurushita,et al. An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.
[286] M. Little,et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells , 2015, mAbs.
[287] Saileta Prabhu,et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.
[288] V. Stoll,et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. , 2007, Blood.
[289] Kiran Mukhyala,et al. Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.
[290] V. Oganesyan,et al. pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling , 2014, The Journal of Biological Chemistry.
[291] P. Humphries,et al. The Blood-Retina Barrier , 2013 .
[292] Rachel M. Devay,et al. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. , 2017, Bioconjugate chemistry.
[293] S. Cooperband,et al. Selective Destruction of Target Cells by Diphtheria Toxin Conjugated to Antibody Directed against Antigens on the Cells , 1970, Science.
[294] Radha Ramakrishnan,et al. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development , 2017, The AAPS Journal.
[295] Theo Rispens,et al. Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.
[296] M. Curran,et al. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..
[297] L. Boulet,et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.
[298] Susan Hua,et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[299] M. van Lookeren Campagne,et al. Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy , 2015, CPT: pharmacometrics & systems pharmacology.